Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that is has received a $1.1M supplement to its $3.1M National Center for Advancing Translational Sciences (NCATS) Award, bringing the total NIH funding to $4.2M. SPI is developing ebselen (SPI-1005), a new molecular entity with anti-viral and anti-inflammatory activity, and enrolling two Phase 2 clinical trials for the treatment of hospitalized COVID-19 patients.
Read More
Sound Pharmaceuticals, Inc. (SPI) is pleased to announce a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1M to support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of patients with COVID-19.
Read More
Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that the FDA has allowed two Phase 2 studies to begin testing ebselen (SPI-1005) in COVID-19 patients. SPI is developing SPI-1005, a novel anti-inflammatory drug which was recently shown to inhibit nCoV2 activity and viral replication.
Read More
Sound Pharmaceuticals (SPI) is pleased to announce the filing of an Investigational New Drug Application with the FDA to begin Phase 2 studies to prevent and treat COVID-19.
Read More
Sound Pharmaceuticals is pleased to announce that the FDA has allowed its pivotal Phase 3 clinical protocol for SPI-1005 in the Treatment of Patients with Meniere’s Disease (STOPMD-3). Read More
University of Oxford and Sound Pharmaceuticals complete Phase 2 Bipolar Disorder Study with SPI-1005
The University of Oxford and Sound Pharmaceuticals (SPI), are pleased to announce the successful completion of a Phase 2a study testing SPI-1005 as a new treatment for bipolar disorder (BPD). Read More
